NeuroGenetic Pharmaceuticals preclinical data

In a transgenic mouse model of AD, once-daily oral NGP 555 for 3 days dose-dependently and significantly reduced beta amyloid 42 levels in both plasma and the brain vs. vehicle-treated controls (p<0....